Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ODIXa-DVTA Prospective, Randomized, Multinational, Multicenter, Partially Blinded, Parallel-group, Open-label Active Comparator Controlled Phase II Dose Finding and Proof of Principle Trial.

NCT00839163 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00839163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00839163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ODIXa-DVTA Prospective, Randomized, Multinational, Multicenter, Partially Blinded, Parallel-group, Open-label Active Comparator Controlled Phase II Dose Finding and Proof of Principle Trial.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
October 31, 2005
Enrollment
613 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis, venous thrombosis